Taspoglutide is a long-acting synthetic GLP-1 receptor agonist active pharmaceutical ingredient (API) designed for the treatment of type 2 diabetes mellitus. It enhances glucose-dependent insulin secretion, suppresses glucagon release, and improves glycemic control through sustained activation of the GLP-1 receptor. It is grouped under the following drug class(es): GLP‑1 Receptor Agonists. The directory classifies it as a discontinued API with a peptide source/manufacturing origin. Other names for this substance include 7-36-Glucagon-like peptide I (human), 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide- and taspoglutidum. Its PubChem CID is 56842233.
Taspoglutide
| CAS No | 275371-94-3 |
|---|---|
| Molecular Formula | C152H232N40O45 |
| Molecular Weight | 3339.7 g/mol |
| Synonyms | (4S)-4-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-2-methyl-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-oxopentanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Taspoglutide is a long-acting synthetic GLP-1 receptor agonist active pharmaceutical ingredient (API) designed for the treatment of type 2 diabetes mellitus. It enhances glucose-dependent insulin secretion, suppresses glucagon release, and improves glycemic control through sustained activation of the GLP-1 receptor.
The listed CAS number is 275371-94-3.
The listed molecular formula is C152H232N40O45.
The listed molecular weight is 3339.7 g/mol.
The source lists 7-36-Glucagon-like peptide I (human), 8-(2-methylalanine)-35-(2-methylalanine)-36-L-argininamide- and taspoglutidum.
It is listed under GLP‑1 Receptor Agonists.